Expression of p57KIP2 potently blocks the growth of human astrocytomas and induces cell senescence

American Journal of Pathology

Volumn 157, Issue 3, 2000, Pages 919-932

  Tsugu, Atsushi ^a   Sakai, Keiichi ^a   Dirks, Peter B ^a   Jung, Shin ^a   Weksberg, Rosanna ^b   Fei, Yan Ling ^b   Mondal, Soma ^a   Ivanchuk, Stacey ^a   Ackerley, Cameron ^b   Hamel, Paul A ^c   Rutka, James T ^a  

^a Arthur and Sonia Labatt Brain Tumour Research Centre   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN P57; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F;

APOPTOSIS; ARTICLE; ASTROCYTOMA; BRAIN TISSUE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL LINE; CELL STRUCTURE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DISEASE MARKER; DOWN REGULATION; GROWTH INHIBITION; HETERODUPLEX ANALYSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM;

EID: 0034495159     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64605-6     Document Type: Article

References (99)

1. Cyclins and cyclin-dependent kinase expression in human astrocytoma cell lines
2. Current concepts in neuro-oncology. The cell cycle - A review
3. WAF1, a potential mediator of p53 tumor suppression
4. p21 is a universal inhibitor of cyclin kinases
5. Cloning of p21Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
6. p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21
7. Low frequency of p57KIP2 mutations in Beckwith-Wiedemann syndrome
8. Cloning of p57kip2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution
9. Cell cycle inhibition by independent CDK and PCNA binding domains in p21cip1
10. p57kip2, a structurally distinct member of the p21cip1 Cdk inhibitory family, is a candidate tumour suppressor gene
11. Genomic imprinting of p57kip2, a cyclin-dependent kinase inhibitor in mouse
12. Selective maternalallele loss in human lung cancers of the maternally expressed p57kip2 gene at 11p15.5
13. Cyclin-dependent kinase inhibitor p57kip2 in soft tissue sarcomas and Wilms' tumor
14. Genomic organization of the human p57kip2 gene and its analysis in the G401 Wilms' tumor assay
15. Human p57kip2 defines a new imprinted domain on chromosome 11p but is not a tumor suppressor gene in Wilms' tumor
16. Reduced expression of the cyclin-dependent kinase inhibitor gene p57kip2 in Wilms' tumor
17. Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen
18. Critical role for the 310 helix region of p57 (kip2) in cyclin-dependent kinase 2 inhibition and growth suppression
19. Cooperation between Cdk inhibitors p27 (KIP1) and p57 (KIP2) in the control of tissue growth and development
20. p21 (CIP1) and p57 (KIP2) control muscle differentiation at the myogenin step
21. p57KIP2 expression and loss of heterozygosity during immortal conversion of cultured human mammary epithelial cells
22. Properties of human malignant glioma cells in vitro
23. Determinants for the establishment of permanent tissue culture lines from human gliomas
24. Formation and growth of multicellular spheroids of human origin
25. Experimental therapy of human glioma by means of a genetically engineered virus mutant
26. Negative effects of wild-type p53 and s-Myc on cellular growth and tumorigenicity of glioma cells. Implication of the tumor suppressor genes for gene therapy
27. Combined radiation and p53 gene therapy of malignant glioma cells
28. Restoration of growth arrest by p161NK4, p21WAF1, pRB, and p53 is dependent on the integrity of the endogenous cell-cycle control pathways in human glioblastoma cell lines
29. Characterization of fetal human brain cultures. Development of a potential model for selectively purifying human glial cells in culture
30. Coding mutations in p57KIP2 are present in some cases of Beckwith Wiedemann syndrome but are rare or absent in Wilm's tumors
31. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters
32. Establishment and characterization of five cell lines derived from human malignant gliomas
33. Effect of retinoids on the proliferation, morphology and expression of glial fibrillary acidic protein of an anaplastic astrocytoma cell line
34. Induction of senescence in human malignant glioma cells by p161NK4A
35. Lymphoproliferation disorder in mice explained by defects in FAS antigen that mediates apoptosis
36. Loss of heterozygosity at a second locus on chromosome 11 in sporadic Wilms' tumor cells
37. Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15
38. Ablation of the CDK inhibitor p57kip2 results in increased apoptosis and delayed differentiation during mouse development
39. Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome
40. p57 (KIP2) polymorphisms and breast cancer risk
41. Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells
42. Astrocyte progression from G1 to S phase of the cell cycle depends upon multiple protein interaction
43. Mutation rate of CDKN2 gene in malignant glioma
44. CDK4 amplification is an alternative mechanism to p16 homozygous deletion in glioma cell lines
45. Deletion of p16 and p15 in brain tumors
46. A cell cycle regulator potentially involved in the genesis of many tumor types
47. Loss of p16 expression is frequent in high grade glioma
48. Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma
49. Retinoic acid and cyclin-dependent kinase inhibitors synergistically alter proliferation and morphology of U343 astrocytoma cells
50. The E2F-family proteins induce distinct cell cycle regulatory factors in p16-arrested, U343 astrocytoma cells
51. The cell cycle and the retinoblastoma protein family
52. The retinoblastoma protein and cell cycle control
53. Regulation of the retinoblastoma protein-related p107 by G1 cyclin complexes
54. Cell cycle regulation by the retinoblastoma family of growth inhibitor proteins
55. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis and G1/S regulatory genes
56. E2F-4, a new member of E2F transcription factor family, interacts with p107
57. The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F
58. E2F-5, a new E2F family member that interacts with p130 in vivo
59. The retinoblastoma protein binds to a family of E2F transcription factors
60. The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner
61. Functional interaction between E2F-4 and p130: Evidence for distinct mechanisms underlying growth suppression by different retinoblastoma protein family members
62. Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells
63. Biological function of the retinoblastoma protein requires distinct domains for hyperphosphorylation and transcription factor binding
64. Identification of a growth suppression domain within the retinoblastoma gene product
65. Replicative senescence, aging, and growth-regulatory transcription factors
66. A biomarker that identifies senescent human cells in culture and in aging skin in vivo
67. Apoptosis: Its significance in cancer and cancer therapy
68. Retinoic acid reduces staurosporine-induced apoptotic damage in chick embryonic neurons by suppressing reactive oxygen species production
69. Characterization of the cell death process induced by staurosporine in human neuroblastoma cell lines
70. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent coombretastatin A-4
71. Activation of CPP32 during apoptosis of neurons and astrocytes
72. Cell death of AKR-2B fibroblasts after serum removal: A process between apoptosis and necrosis
73. Ceramide induces apoptosis in immature cerebellar granule cells in culture
74. Transforming growth factor-beta1 induces apoptotic cell death in cultured retinal endothelial cells but not pericytes: Association with decreased expression of p21waf1/cip1
75. Chemotherapy primes malignant glioma cells for CD95 ligand-induced apoptosis up-stream of caspase 3 activation
76. Combination therapy with cisplatin and nifedipine inducing apoptosis in multidrug-resistant human glioblastoma cells
77. Interleukin-1 beta-converting enzyme mediates cisplatin-induced apoptosis in malignant glioma cells
78. Evaluation of apoptosis in four human tumour cell lines with differing sensitivities to cisplatin
79. Ionizing radiation inhibits chemotherapy-induced apoptosis in cultured glioma cells: Implications for combined modality therapy
80. Human gliomas with wild-type p53 express bcl-2
81. Identification of a novel Bcl-2 related gene, BRAG-1, in human glioma
82. Expression of bcl-2 in reactive and neoplastic astrocytes: Lack of correlation with presence or degree of malignancy
83. Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene
84. Differential activity of bcl-2 and ICE enzyme family protease inhibitors on Fas and puromycin-induced apoptosis of glioma cells
85. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines
86. Restoration of growth arrest by p16, p21, pRB and p53 is dependent on the integrity of the endogenous cell cycle control pathways in human glioblastoma cell lines
87. Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines
88. p53-independent anisomycin induced G1 arrest and apoptosis in L1210 cell lines
89. Immunohistochemical analysis of p53 and p21 in human primary glioblastomas in relation to proliferative potential and apoptosis
90. Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors
91. Apoptosis and p53 expression in human gliomas
92. Mutant p53 can provoke apoptosis in p53-deficient Hep3B cells with delayed kinetics relative to wild-type p53
93. Irradiation induces G2/M cell cycle arrest and apoptosis in p53-deficient lymphoblastic leukemia cells without affecting Bcl-2 and Bax expression
94. Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells
95. Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis
96. p53-dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells
97. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis
98. Yama/CPP32b, a mammalian homolog of ced-3, is a CrmA-inhibitable protease that cleaves the death substrate Poly(ADP-ribose) polymerase
99. Down-regulation of Ku autoantigen, DNA-dependent protein kinase, and poly(ADP-ribose) polymerase during cellular senescence